Prelim Results revised date, guidance unchanged

2020 Preliminary Results revised date, guidance unchanged

Chippenham, UK - 5 March 2021: Vectura Group plc (LSE: VEC) ("Vectura", "the Group") today announces a revised date for the publication of its Preliminary Results for the full year ended 31 December 2020.

The Group's auditor, KPMG LLP, has advised Vectura that it has experienced unforeseen delays in completing its audit as a result of recent resourcing constraints arising from COVID-19. As such, it has requested additional time to complete its audit procedures. The Group will now announce its Preliminary Results on 18 March 2021. Vectura confirms that the delay has not arisen as a result of concerns relating to the 2020 financial results or the future outlook of the Group.

As announced in the Group's January trading update, financial performance for 2020 was ahead of Board expectations.

Will Downie, Chief Executive Officer, and Paul Fry, Chief Financial Officer will host a live webcast and conference call for analysts at 9:30am GMT on 18 March 2021.

Access to the webcast and presentation slides will be made available on Vectura's website.

- Ends -

For more information, please contact:

Vectura Group plc

Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565

David Ginivan - VP Corporate Communications +44 (0)7471 352 720

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Olivia Manser / Melissa Gardiner / David Daley

About Vectura

Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has twelve key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com